China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
LOS ANGELES, March 18, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq:STML) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.
When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
